No | Structure | COMMON NAME | NAME | DATA No | INFORMANT | SYMBOL | FORMULA | MOL.WT(ave) | Download | BIOOGICAL ACTIVITY | PHYSICAL AND CHEMICAL PROPERTIES | SPECTRAL DATA | CHROMATOGRAM DATA | SOURCE | CHEMICAL SYNTHESIS | METABOLISM | GENETIC INFORMATION | NOTE | REFERENCES | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MELTING POINT | BOILING POINT | DENSITY | REFRACTIVE INDEX | OPTICAL ROTATION | SOLUBILITY | UV SPECTRA | IR SPECTRA | NMR SPECTRA | MASS SPECTRA | OTHER SPECTRA | ||||||||||||||||||
1 | vitamin K1 / 3-phytylmenadione / phytomenadione / phylloquinone |
2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione / 2-methyl-3-phytyl-1,4-naphthoquinone |
VVK0001 | Tetsuya Nakamura |
VK1 |
C31H46O2 | 450.696 | Involvement of vitamin K-dependent clotting factors in coagulation. The vitamin K-dependent proteins ( ellipses) circulate as inactive forms of serine proteases until converted to their active (subscript a) forms. These conversions occur in stages where an active protease, a substrate, and a protein cofactor (triangles) from a Ca2+-mediated association with a phospholipid surface. The protein cofactors V and VII are activated by thrombin (IIa) to achieve their full activity. The clotting system is traditionally divided into two pathways: the extrinsic pathway which involves a tissue factor (TO) in addition to blood components, and an intrinsic pathway, which involves components present in the blood. Protein C is activated by Ida in the presence of an endothelial cell protein called thrombomodulin (TM). Protein C is not a procoagulant but rather functions in a complex with protein S to inactivate Va and VIIIa [Table 0007] (Ref. 0006). |
Yellow viscous oil (Ref. 0001) |
n20D=1.5263(Ref. 0010) |
Insol in water. Sparingly sol in methanol; sol in ethanol, acetone, benzene, petr ether, hexane, dioxane, chloroform, ether, other fat solvents and in vegetable oils(Ref. 0001) |
(liquid) : 6.05m (CO), 6.21, 6.28m (aromatic nucleus) (Ref. 0008) [Spectrum 0002] (Ref. 0010) [Table 0002] (Ref. 0010) |
at 60 MHz in CDCl3, i nternal standard Si(CH3)4: multiplet at 453-486 Hz (4 aromatic H), triplet at 302 Hz (J=7 Hz) (olefinic H at C2. , doublet at 201 Hz ) (J=7 Hz) (CH2.-1), singlet at 130 Hz (CH3-2), signal at 107 Hz (trans-methyl group at C3. .(Ref. 0008) [Spectrum 0003] (Ref. 0010) Proton magnetic resonance data [Table 0003] (Ref. 0010> |
The content of vitamin K1 (phylloquinone) was determined in 27 species of green vegetables by HPLC and correlation between Vitamin K1 content and chlorophyll content was investigated. The ratio of vitamin K1 to chlorophyll was about 9 mmol/mol. VK1 content (mg/100g fresh wt.): Parsley (0.73), Perilla (Leaves) (0.65), Ashitaba (Leaves) (0.59), Watercress (0.39), Toumyao (Chinese vegetable) (0.38), Mitsuba (Leaf stalk and leaves) (0.37) [Table 0004] (Ref. 0007) Vitamin K contents in human liver [Table 0005] (Ref. 0022) |
To a dichloromethane solution (20ml) of 2-methyl-1,4-naphthoquinone (172mg, 1.0mmol) BF3.Et2O (3.0mmol) was added under N2 at -78 C. After that phytyltrimethyltin was (532mg, 1.2mmol) was added, and the temperature of the resulting solution was gradually elevated within 1h. Then, ether and aqueous saturated NaCl solution were added to the reaction mixture. The organic layer and the combined ether extract were dried over anhydrous magnesium sulfate. Subsequent oxidation with excess silver oxide gave crude vitamin K1 after solvent was evaporated in vacuo. The resulting crude product was purified by preparative TLC on silica gel; affording vitamin K1(176mg) (Ref. 0009) [Table 0006] (Ref. 0008). |
The synthesis of prothrombin in Chinese hamster ovary cells stably transfected with the prothrombin c DNA by immunofluorescent staining. Uncarboxylated proprothrombin undergoes complete g- carboxylation in the endoplasmic reticulum and that g- carboxylation precedes propeptide cleavage during prothrombin biosynthesis (Ref. 0011). |
||||||||||||
2 | Menaquinone 1. |
1,4-Naphthalenedione, 2-methyl-3-(3-methyl-2-butenyl)- / 1,4-Naphthoquinone, 2-methyl-3-(3-methyl-2-butenyl)- |
VVK0002 | Tetsuya Nakamura |
MK-1 |
C16H16O2 | 240.297 | n20D=1.5840(Ref. 0010) |
lmax, 248.5 mm, 1%1cm =756(Ref. 0010) |
Condensation of 2-methyl-1,4-naphthohydroquinone (I) with methylbutenol (II). I (27.5g) is dissolved in 65 ml of dry dioxane, 1.5 g of zinc chloride, and 3.5 ml of borontrifluoride etherate are added with stirring, and the mixture is heated to 50. A solution of 0.87 mole of II per mole of I in 25 ml of dry dioxane is added, and the reaction mixture is stirred for 20 min longer. After cooling water and ether are added, the layers were separated and the etheral layer is washed. The ether solution is evaporated. The residue is dissolved in 200 ml of petroleum ether, the solution cooled to -50. The precipitate centrifuged. The precipitate dissolved in 100 ml of ether, 20 g of dry silver oxide is added and the mixture shaken for 30 min. After filtration the etheral solution is evaporated in vacuo, the residue dissolved in petroleum ether and chramatogphed. (Ref. 0017) |
||||||||||||||||||
3 | Menaquinone 2 / Vitamin K2(10) |
1,4-Naphthalenedione, 2-(3,7-dimethyl-2,6-octadienyl)-3-methyl- / 1,4-Naphthoquinone, 2-(3,7-dimethyl-2,6-octadienyl)-3-methyl- |
VVK0003 | Tetsuya Nakamura |
MK-2 |
C21H24O2 | 308.414 | 53(Ref. 0010) |
E1%1cm (248mm) =613-617, in ethanol ; petroleum ether(Ref. 0010) |
Condensation of 2-methyl-1,4-naphthohydroquinone (I) with linalool (II). I (27.5g) is dissolved in 65 ml of dry dioxane, 1.5 g of zinc chloride, and 3.5 ml of borontrifluoride etherate are added with stirring, and the mixture is heated to 50. A solution of 0.87 mole of II per mole of I in 25 ml of dry dioxane is added, and the reaction mixture is stirred for 20 min longer. After cooling water and ether are added, the layers were separated and the etheral layer is washed. The ether solution is evaporated. The residue is dissolved in 200 ml of petroleum ether, the solution cooled to -50. The precipitate centrifuged. The precipitate dissolved in 100 ml of ether, 20 g of dry silver oxide is added and the mixture shaken for 30 min. After filtration the etheral solution is evaporated in vacuo, the residue dissolved in petroleum ether and chramatogphed. (Ref. 0017) |
||||||||||||||||||
4 | Menaquinone 3 / Vitamin K2(15)/ Vitamin MK3 |
1,4-Naphthalenedione, 2-methyl-3-(3,7,11-trimethyl-2,6,10-dodecatrienyl)- / 1,4-Naphthoquinone, 2-methyl-3-(3,7,11-trimethyl-2,6,10-dodecatrienyl)- |
VVK0004 | Tetsuya Nakamura |
MK-3 |
C26H32O2 | 376.531 | 35C(Ref. 0010) |
n20D=1.5588(Ref. 0010) |
E1%1cm (248mm) =496, in petroleum ether(Ref. 0010) |
Condensation of 2-methyl-1,4-naphthohydroquinone (I) with nerolidol (II). I (27.5g) is dissolved in 65 ml of dry dioxane, 1.5 g of zinc chloride, and 3.5 ml of borontrifluoride etherate are added with stirring, and the mixture is heated to 50. A solution of 0.87 mole of II per mole of I in 25 ml of dry dioxane is added, and the reaction mixture is stirred for 20 min longer. After cooling water and ether are added, the layers were separated and the etheral layer is washed. The ether solution is evaporated. The residue is dissolved in 200 ml of petroleum ether, the solution cooled to -50. The precipitate centrifuged. The precipitate dissolved in 100 ml of ether, 20 g of dry silver oxide is added and the mixture shaken for 30 min. After filtration the etheral solution is evaporated in vacuo, the residue dissolved in petroleum ether and chramatogphed. (Ref. 0017) |
|||||||||||||||||
5 | Menaquinone 4 / Vitamin K2(20) / Vitamin MK4 / Menaquinone MK4 / Kaytwo / Menatetrenone. |
1,4-Naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)- / 1,4-Naphthoquinone, 2-methyl-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)- |
VVK0005 | Tetsuya Nakamura |
MK-4 |
C31H40O2 | 444.648 | Menatetrenone at greater than 3 x 10 -6 M significantly inhibited the calcium release from mouse calvaria induced by 2 x 10 -10M of 1,25 (OH)2D3 or 10 -7M of prostaglandin E2, and also inhibited osteoclast-like multinuleated cell formation induced by 10 -8M of 1,25(OH)2D3 in co-culture of spleen ells and stromal cells at the same concentrations. The inhibitory effect f menaterenone on the calcium release from calvaria was not affected by the addition of 3 x 10-5M of warfarin an inhibtor of vitamin K cycle. (Ref. 0018) |
35C(Ref. 0001) |
E1%1cm (248mm) =438-440, in petroleum ether(Ref. 0001) |
Rats were made vitamin K-deficiency by feeding them diet devoid of vitamin K. after one week, circulating prothrombin concentrations were between 5 and 10% of initial values and various amounts of phylloquinone, menaquinone-4, and menaquinone-9 were given in a single dose either subcutaneously, orally, or colorectally. The relative 'vitamin K acitivties' of these compounds were assessed by comparing their activity to support prothrombin synthesis after subcutaneous injection. The stimulation of prothormbin synthesis by menaquinone-9 lasted much longer than that by the two other K-vitamers, resulting in a substantially higher 'vitamin K activity' of menaquinone-9.(Ref. 0032) [Table 0001] (Ref. 0032) |
Condensation of 2-methyl-1,4-naphthohydroquinone (I) with geranyllinalool (II). I (27.5g) is dissolved in 65 ml of dry dioxane, 1.5 g of zinc chloride, and 3.5 ml of borontrifluoride etherate are added with stirring, and the mixture is heated to 50. A solution of 0.87 mole of II per mole of I in 25 ml of dry dioxane is added, and the reaction mixture is stirred for 20 min longer. After cooling water and ether are added, the layers were separated and the etheral layer is washed. The ether solution is evaporated. The residue is dissolved in 200 ml of petroleum ether, the solution cooled to -50. The precipitate centrifuged. The precipitate dissolved in 100 ml of ether, 20 g of dry silver oxide is added and the mixture shaken for 30 min. After filtration the etheral solution is evaporated in vacuo, the residue dissolved in petroleum ether and chramatogphed. (Ref. 0017) |
Four metabolites of menaquinone-4 (MQ-4) were isolated from rat urine, bile and liver, and identified. On the basis of their structures, the metabolic pathways of MQ-4 are proposed as shown in [Table 0002]. This pathway begins with w-methyl oxidation of the side chain followed by b-oxidation of the resultant MQ-4-COOH to K acid 1 and K acid 2. In the presence of warfarin, 2,3-epoxy-phylloquinone. This suggests that 2,3-epoxy-MQ-4 is converted to MQ-4 in the normal rat and that the reaction is inhibited by warfarin.(Ref. 0003) |
|||||||||||||||
6 | Menaquinone 5 / Vitamin K2(25) / Vitamin MK5 / Menaquinone 5. |
1,4-Naphthalenedione, 2-methyl-3-(3,7,11,15,19-pentamethyl-2,6,10,14,18-eicosapentaenyl)- / 1,4-Naphthoquinone, 2-methyl-3-(3,7,11,15,19-pentamethyl-2,6,10,14,18-eicosapentaenyl)- |
VVK0006 | Tetsuya Nakamura |
MK-5 |
C36H48O2 | 512.765 | 39C (Ref. 0010) |
E1%1cm (248mm) =363, in petroleum ether(Ref. 0010) |
Condensation of 2-methyl-1,4-naphthohydroquinone (I) with farnesyllinalool (II). I (27.5g) is dissolved in 65 ml of dry dioxane, 1.5 g of zinc chloride, and 3.5 ml of borontrifluoride etherate are added with stirring, and the mixture is heated to 50. A solution of 0.87 mole of II per mole of I in 25 ml of dry dioxane is added, and the reaction mixture is stirred for 20 min longer. After cooling water and ether are added, the layers were separated and the etheral layer is washed. The ether solution is evaporated. The residue is dissolved in 200 ml of petroleum ether, the solution cooled to -50. The precipitate centrifuged. The precipitate dissolved in 100 ml of ether, 20 g of dry silver oxide is added and the mixture shaken for 30 min. After filtration the etheral solution is evaporated in vacuo, the residue dissolved in petroleum ether and chramatogphed. (Ref. 0017) |
||||||||||||||||||
7 | Menaquinone 6 / Vitamin K2(30)/ Vitamin MK6 / Menaquinone K6 / Farnoquinone. |
1,4-Naphthalenedione,2-methyl-3-(3,7,11,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaenyl)- / 1,4-Naphthoquinone,2-methyl-3-(3,7,11,15,19,23--hexamethyl-2,6,10,14,18,22-tetracosahexaenyl)- |
VVK0007 | Tetsuya Nakamura |
MK-6 |
C41H56O2 | 580.882 | 50C(Ref. 0010) |
E1%1cm (248mm) =320-321, in petroleum ether(Ref. 0010) |
Condensation of 2-methyl-1,4-naphthohydroquinone (I) with farnesylnerolidol (II). I (27.5g) is dissolved in 65 ml of dry dioxane, 1.5 g of zinc chloride, and 3.5 ml of borontrifluoride etherate are added with stirring, and the mixture is heated to 50. A solution of 0.87 mole of II per mole of I in 25 ml of dry dioxane is added, and the reaction mixture is stirred for 20 min longer. After cooling water and ether are added, the layers were separated and the etheral layer is washed. The ether solution is evaporated. The residue is dissolved in 200 ml of petroleum ether, the solution cooled to -50. The precipitate centrifuged. The precipitate dissolved in 100 ml of ether, 20 g of dry silver oxide is added and the mixture shaken for 30 min. After filtration the etheral solution is evaporated in vacuo, the residue dissolved in petroleum ether and chramatogphed. (Ref. 0017) |
||||||||||||||||||
8 | Menaquinone 7 / Vitamin K2 (35)/ Vitamin MK7 / Menaquinone K7. |
1,4-Naphthalenedione,2-methyl-3-(3,7,11,15,19,23,27-heptamethyl-2,6,10,14,18,22,26-octacosaheptaenyl)- / 1,4-Naphthoquinone,2-methyl-3-(3,7,11,15,19,23,27-heptamethyl-2,6,10,14,18,22,26-octacosaheptaenyl)- |
VVK0008 | Tetsuya Nakamura |
MK-7 |
C46H64O2 | 648.999 | 54C(Ref. 0010) |
Condensation of 2-methyl-1,4-naphthohydroquinone (I) with farnesylgeranyllinalool (II). I (27.5g) is dissolved in 65 ml of dry dioxane, 1.5 g of zinc chloride, and 3.5 ml of borontrifluoride etherate are added with stirring, and the mixture is heated to 50. A solution of 0.87 mole of II per mole of I in 25 ml of dry dioxane is added, and the reaction mixture is stirred for 20 min longer. After cooling water and ether are added, the layers were separated and the etheral layer is washed. The ether solution is evaporated. The residue is dissolved in 200 ml of petroleum ether, the solution cooled to -50. The precipitate centrifuged. The precipitate dissolved in 100 ml of ether, 20 g of dry silver oxide is added and the mixture shaken for 30 min. After filtration the etheral solution is evaporated in vacuo, the residue dissolved in petroleum ether and chramatogphed. (Ref. 0017) |
|||||||||||||||||||
9 | Menaquinone 8 / Menaquinone MK8/ Vitamin K2(40)/ Vitamin MK8. |
1,4-Naphthalenedione,2-methyl-3-(3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaenyl)- / 1,4-Naphthoquinone,2-methyl-3-(3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaenyl)- |
VVK0009 | Tetsuya Nakamura |
MK-8 |
C51H72O2 | 717.116 | 56C(Ref. 0010) |
E1%1cm (248mm)= 268, in petroleum ether(Ref. 0010) |
Condensation of 2-methyl-1,4-naphthohydroquinone (I) with farnesylfarnesyllinalool (II). I (27.5g) is dissolved in 65 ml of dry dioxane, 1.5 g of zinc chloride, and 3.5 ml of borontrifluoride etherate are added with stirring, and the mixture is heated to 50. A solution of 0.87 mole of II per mole of I in 25 ml of dry dioxane is added, and the reaction mixture is stirred for 20 min longer. After cooling water and ether are added, the layers were separated and the etheral layer is washed. The ether solution is evaporated. The residue is dissolved in 200 ml of petroleum ether, the solution cooled to -50. The precipitate centrifuged. The precipitate dissolved in 100 ml of ether, 20 g of dry silver oxide is added and the mixture shaken for 30 min. After filtration the etheral solution is evaporated in vacuo, the residue dissolved in petroleum ether and chramatogphed. (Ref. 0017) |
||||||||||||||||||
10 | Menaquinone 9 / Menaquinone MK9 / Vitamin K2 (45) / Vitamin MK9. |
1,4-Naphthalenedione,2-methyl-3-(3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonaenyl)- / 1,4-Naphthoquinone,2-methyl-3-(3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonaenyl)- |
VVK0010 | Tetsuya Nakamura |
MK-9 |
C56H80O2 | 785.233 | 56-57C(Ref. 0017) |
E1%1cm (248mm) =246, in petroleum ether, 80-105(Ref. 0017) |
Seven grams of 2-methyl-1,4-naphthohydroquinone (I) is dissolved in 50 ml of dry dioxane, 0.5 g of zinc chloride and 1 ml of boron trifluoride etherate in 65 ml of dry dioxane, 1.5 g of zinc chloride of borontrifluoride etherate are added with stirring, and the mixture is heated to 55 - 60 under nitrogen. A solution of 7.5 g of solanesol in 30 ml of dry dioxane is added, and the reaction mixture is stirred for 1 hour longer. After cooling water and ether are added, the layers were separated and the etheral layer is washed. The ether solution is evaporated. The residue is dissolved in 200 ml of ether, 10 g of dry silver oxide is added and the mixture shaken for 30 min. After filtration the etheral solution is evaporated in vacuo, the residue dissolved in petroleum ether and chramatogphed through a colum of aluminum oxide. Yield : 120 mg. m.p. 56-57. (Ref. 0017) |
Rats were made vitamin K-deficiency by feeding them diet devoid of vitamin K. after one week, circulating prothrombin concentrations were between 5 and 10% of initial values and various amounts of phylloquinone, menaquinone-4, and menaquinone-9 were given in a single dose either subcutaneously, orally, or colorectally. The relative 'vitamin K acitivties' of these compounds were assessed by comparing their activity to support prothrombin synthesis after subcutaneous injection. The stimulation of prothormbin synthesis by menaquinone-9 lasted much longer than that by the two other K-vitamers, resulting in a substantially higher 'vitamin K activity' of menaquinone-9.(Ref. 0032) [Table 0003] (Ref. 0032) |
|||||||||||||||||
11 | Menaquinone 10 / Menaquinone MK10 / Vitamin K2(50) / Vitamin MK10. |
1,4-Naphthalenedione,2-methyl-3-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)- / 1,4-Naphthoquinone,2-methyl-3-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)- |
VVK0011 | Tetsuya Nakamura |
MK10 |
C61H88O2 | 853.350 | E1%1cm (248mm) =224, in petroleum ether, b.p. 80-105.(Ref. 0017) |
Concentration in human liver [Table 0001] (Ref. 0022). Distribution in human mitochondrial and microsomal fractions [Table 0002] (Ref. 0022). |
Menaquinone-10 (Ref. 0011) is prepared in analogy to menaquinone-9 (Ref. 0010) from 7g of farnesylfarnesylgeranyllinalool, 7 g of 2-methyl-1,4-naphthohydroquinone (I) is dissolved in 50 ml of dry dioxane, 0.5 g of zinc chloride and 1 ml of boron trifluoride etherate in 65 ml of dry dioxane, 1.5 g of zinc chloride of borontrifluoride etherate are added with stirring, and the mixture is heated to 55 - 60 under nitrogen. The crude product, m.p. 56., is chromatographed on Hostalen, yielding pure menaquinone-10 as fine yellow crystals, melting at 62. (Ref. 0017) |
||||||||||||||||||
12 | Menaquinone 11/ Menaquinone MK11 / Vitamin K2(55) / Vitamin MK11. |
VVK0012 | Tetsuya Nakamura |
MK11 |
C66H96O2 | 921.467 | Concentration in human liver [Table 0001] (Ref. 0022). Distribution in human mitochondrial and microsomal fractions [Table 0002] (Ref. 0022). |
|||||||||||||||||||||
13 | Menaquinone 12/ Menaquinone MK12 / Vitamin K2(60) / Vitamin MK12. |
1,4-Naphthalenedione, 2-methyl-3-2-(3,7,11,15,19,23,27,31,35,39,43,47-dodecamethyl- 2,6,10,14,18, 22,26,30,34,38,42,46-octatetracontadodecaenyl)-/ 1,4-Naphthoquinone, 2-methyl-3-2-(3,7,11,15,19,23,27,31,35,39,43,47-dodecamethyl- 2,6,10,14,18, 22,26,30,34,38,42,46-octatetracontadodecaenyl)- |
VVK0013 | Tetsuya Nakamura |
MK12 |
C71H104O2 | 989.584 | Concentration in human liver [Table 0001] (Ref. 0022). Distribution in human mitochondrial and microsomal fractions [Table 0002] (Ref. 0022). |
||||||||||||||||||||
14 | Menaquinone 13/ Menaquinone MK13 / Vitamin K2(65) / Vitamin MK13. |
1,4-Naphthalenedione, 2-methyl-3-2-(3,7,11,15,19,23,27,31,35,39,43,47,51-tridecamethyl- 2,6,10,14,18, 22,26,30,34,38,42,46-octatetracontadodecaenyl)-/ 1,4-Naphthoquinone, 2-methyl-3-2-(3,7,11,15,19,23,27,31,35,39,43,47,51-tridecamethyl- 2,6,10,14,18, 22,26,30,34,38,42,46,50-dopentacontatridecaenyl)- |
VVK0014 | Tetsuya Nakamura |
MK13 |
C76H112O2 | 1057.701 | Human liver MK-13 concentration was determined by HPLC using platinum-back catalyst reduction and fluorimetric detection [Table 0001] (Ref. 0022). MK-13 concentrations in human mitochondrial and microsomal fractions were analyzed by the same procedure [Table 0002] (Ref. 0022). |
||||||||||||||||||||
15 | Menaquinone 14/ Menaquinone MK14 / Vitamin K2(70) / Vitamin MK14. |
VVK0015 | Tetsuya Nakamura |
MK14 |
C81H120O2 | 1125.818 | ||||||||||||||||||||||
16 | Vitamin K1 2,3-oxide / Vitamin K1 2,3-epoxide / 1,4-Naphthoquinone, 2,3-epoxy2,3-dihydro-2-methyl-3-phytyl- / 2,3-Epoxyphylloquinone / Phylloquinone oxide / Phylloquinone, epoxide / Phylloquinone-2,3-epoxide. |
1a, 7a-Dihydro-7a-methyl-1a-(3,7,11,15-tetramethyl-2-hexadecyl)naphth[2,3-b]oxirene-2,7-dione / 2-methyl-3-phytyl1,4-naphthoquinone 2,3-oxide |
VVK0016 | Tetsuya Nakamura |
C31H46O3 | 466.695 | uv max (95% alc): 259, 305 nm (log EM 3.79, 3.31)(Ref. 0026). |
|||||||||||||||||||||
17 | Vitamin K5 / Synkamin base / Vitamin K5 base. |
4-Amino-2-methyl-1-naphthalenol / 4-amino-2-methyl-1-naphthol / 1-hydroxy-2-methyl-4-aminonaphthalene / 2-methyl-4-amino-1-hydroxynaphthalene / 2-methyl-4-amino-1-naphthol / 3-methyl-4-hydroxy-1-naphththylamine. |
VVK0017 | Tetsuya Nakamura |
C11H11NO | 173.211 | By heating, 187.5 g of stannous chloride are dissolved in 800 cm3 of concentrated hydrochloric acid (d=1.19). To the hot solution a suspension of 60 g of the monoxime of 2-methyl-1,4-naphthoquinone in 250 cm3 of warm concentrated hydrochloric acid is added. The desired hydrochloride separates out and the reaction mixture stirred for about 5 minutes. When the temperature has fallen to 50C the substance is filtered rapidly (Schott G3 glass filter) and washed three times with 125 cm3 of 4n hydrochloric acid. The crude compound is dissolved in a solution of 30 g of potassium metabisulphite in 750 cm3 of water, and after treating with charcoal, the pure hydrochloride is precipitated by means of 600 cm3 of concentrated hydrochloric acid to which 6 g of potassium metabisulphite have been added. The substance is filtrated by suction (glass filter), washed three times with 100 cm3 of 4n hydrochloric acid, then with 60 cm3 of alcohol and dried in vacuo over potassium hydroxide. Yield 50 g (75%).(Ref. 0041) |
|||||||||||||||||||||
18 | Vitamin K6 |
2-Mthyl-1,4-naphthalenediamine / 1,4-diamino-2-methylnaphthalene / 2-methyl-1,4-diaminonaphthalene. |
VVK0018 | Tetsuya Nakamura |
C11H12N2 | 172.226 | 300C (blackening)(Ref. 0041) |
A suspension of 40 g of 1-amino-2-methyl-4-p-sulphophenylazo-naphthalenee in 200 cm3 of concentrated hydrochloric acid (d=1.19) is added to a hot solution of 75 g of stannous chloride in 400 cm3 of hydrochloric acid (d=1.19). The mixture is boiled until it has become colorless, with the occasional addition of a piece of spongy tin. After adding 500 cm3 of hydrochloric acid (d=1.19) and cooling, the white crystalline material filtered by suction and washed three times with 100 cm3 of hydrochloric acid (d=1.19). The substance is dissolved in a solution of 3 g of K2S2O5 in 300 cm3 of water, decolorlized with charcoal, and after filtration the pure dihydrochloride precipitated by adding 300 cm3 of hydrochloric acid (d=1.19). After cooling to 0C the compound is filtered by suction, washed three times with 50 cm3 of 4n hydrochloric acid, then with 150cm3 of alcohol and dried in vacua over potassium hydroxide. Yield 20g. (70%).(Ref. 0041) |
||||||||||||||||||||
19 | Vitamin K7 |
4-Amino-3-methyl-1-naphthalenol / 4-amino-3-methyl--1-naphthol / 1-hydroxy-3-methyl-4-aminonaphthalene / 3-methyl-4-amino-1-naphthol / 2-methyl-4-hydroxy-1-naphthylamine / 1-amino-2-methyl-4-naphthol. |
VVK0019 | Tetsuya Nakamura |
VK7 |
C11H11NO | 173.211 | 3-Methyl-1-naphthol (4 g) was treated with solution prepared by diazotizing 5.3 g of sulfanilic acid, the azo derivative was reduced with 16 g of sodium dithionite and the precipitated aminonaphtol, purified by recrystallization from hydrochloric acid containing stannous chloride, yielded 3.4 g of pure 1-amino-2-methyl -4-naphthol hydrochloride (charred at 270). (Ref. 0016) |
||||||||||||||||||||
20 | Menadiol / dihydrovitamin K3 |
2-Methyl-1,4-naphthalenediol / 2-methyl-1,4-naphthohydroquinone / 2-methyl-1,4-naphthoquinol . |
VVK0020 | Tetsuya Nakamura |
C11H10O2 | 174.196 | 181(Ref. 0021) |
The quinone (2gm) is dissolved in 35cc of ether by warming and the solution is poured into a separatory funnel and shaken with a fresh solution of 4 gm of sodium hydrosulfite in 30 cc of water. After the mixture is shaken for a few minutes, the solution passes through a brown phase (quinhydrone) and becomes pale yellow. After removal of the aqueous layer the ethereal solution shaken with a mixture of 25 cc of saturated sodium chloride solution and 1 to 2 cc of saturated hydrosufite solution to remove the bulk of the water and filtered by gravity through a paper moistened with ether and about one-third filled with an hydrous magnesium (or sodium ) sulfate. The filtrate is evaporated until nearly all of the ether has been removed, cooled, and treated with petroleum ether (b.p. 20-40). The hydroquinone separating as a white or grayish powder is washed with petroleum ether and air-dried ; yield, 1.9 gm (94 per cent).(Ref. 0038) |
||||||||||||||||||||
21 | Acetomenaphthone / menadiol diacetate / vitamin K4/ /Kapilin / Prokayvit Oral / Vitavel K / davitaminon-K / Kappaxan / Kayvite. |
1,4-Diacetoxy-2-methylnaphthalene. |
VVK0021 | Tetsuya Nakamura |
C15H14O4 | 258.269 | 112 - 114(Ref. 0021) |
Practically insol in water. Slightly sol in cold alc; sol in 3.3 parts boiling alc, in aceitc acid.(Ref. 0021) |
||||||||||||||||||||
22 | Menadiol dibutyrate / Karanum. |
2-Methyl-1,4-naphthalenediol dibutyrate / 2-methyl-1,4-naphthohydroquinone dibutyrate. |
VVK0022 | Tetsuya Nakamura |
C19H22O4 | 314.376 | about 53(Ref. 0019) |
|||||||||||||||||||||
23 | Menadiol diphosphate (Tetrasodium salt) / menadiol tetrasodium diphosphoric acid ester / menadiol sodium diphosphate / menadione diphosphate tetrasodium salt / Kappadione / Kipca , water soluble / Procoagulo / Synka-vit. / Synkavite. |
2-Methyl-1,4-naphthalenediol diphosphoric acid ester tetrasodium salt / 2-methyl-1,4-naphthohydroquinone diphosphoric acid ester tetrasodium salt / tetrasodium 2-methyl-1,4-naphthohydroquinone diphosphoric acid ester. |
VVK0023 | Tetsuya Nakamura |
C11H8Na4O8P2 | 422.083 | A solution of 0.3 g of the hydroquinone in 0.8 cc of pyridine was added by drops with ice cooling to a suspension prepared by addling 0.5 cc of phosphorous oxychloride with cooling to 1 cc of pyridine. At the end the mixture was allowed to warm up until the exohthermic reaction was over. The white suspension was then treated with 6 cc of water, added cautiously at first with ice cooling and later heating to dissolve the product. Sodium carbonate was added until alkaline litmus and the pyridine layer which separated was removed. The solution of sodium salts was stirred with absolute alcohol and the solvent decanted, leaving an aqueous solution of greatly diminshed volume. The remainder of the water can be removed by stirring either with fresh portions of alcohol or with smaller portions of pyridine , leaving the sodium salt as a gum.(Ref. 0036) |
Physiological doses of radioactive menadiol diphosphate, an active water-soluble form of vitamin K, were administered by intraperitoneal injection to vitamin K-deficient male rats. The compound was not concentrated by any tissue but was distributed throughout all body organs in manner which was not influenced by the vitamin K status of the animal. Seventeen hours after an intraperitoneal injection of the radioactive vitamin about 50 % of the activity had been excreted, mainly in the urine. There was a general association of the injected compound or its metabolites with the membranous fractions of the cell. The data also indicate that there was a rapid conversion of this water-soluble compound to more lipophilic forms of the vitamin.(Ref. 0037) |
||||||||||||||||||||
24 | Sodium menadiol disulfate |
Sodium 2-methyl-1,4-naphthohydroquinone disulfate. |
VVK0024 | Tetsuya Nakamura |
C11H8O8S2Na2 | 378.288 | A mixture of 0.5 g of 2-methyl-1,4-naphthohyrdroquinone with a cooled suspension from 1 cc of pyridine, 10 cc of carbon tetrachloride and 0.5 cc of chlorosulfonic acid was heated for ten minutes on the steam-bath, cooled, and the solvent decanted from the oily yellow pyridine salt. This was treated with a slight excess of 10 N alkalin the mixture was extracted with ether, and the residual red oil taken up in a little hot water. Alcohol added in portions precipitated first inorganic material which was removed, and then the ester salt as tan crystals (0.58 g, 0.27 g more from the mother liquor). Crystallization from water gave 0.4 g of colorless product free from inorganic salts, and this was further purified by dissolving it in water and adding alcohol. The air dried material proved to be a dihydrate.(Ref. 0036) |
|||||||||||||||||||||
25 | menaphthone / vitamin K3 / Kanone / Kappaxin / Kayklot / Kayquinone / Klottone / Kolklot / Thyloquinone |
2-Methyl-1,4-naphthalenedione / 2-methyl-1,4-naphthoquinone. |
VVK0025 | Tetsuya Nakamura |
VK3 |
C11H8O2 | 172.180 | 105 -107(Ref. 0020) |
Insoluble in water. One gram dissolves in about 60 ml alcohol, in 10 ml benzene, in 50 ml vegetable oils; moderately sol in chloroform and in carbon tetrachloride(Ref. 0020) |
[SP0002] (Ref. 0010) . |
[SP0003] (Ref. 0010) |
To a solution of 10.0 g (70.3 mmol) of 2-methylnaphthalene and 349 mg (1.40 mmol) of methyltrioxorhenium in 150 ml of acetic acid was added drop wise at room temperature 14.3 ml (0.49 mol) of 85% H2 O2. The reaction mixture was allowed to stir at 40 C for 4 h under a N2 atmosphere, before 100 ml of water was added. The mixture was extracted with CH2 Cl22 (3 x 200 ml). The combined organic phases were washed with 150 ml of water, dried over Na2SO4 and concentrated at 20-40C/10-20 Torr. The quinone products were separated from the starting material by column chromatography. Recrystallization of the chromatographed product from ethanol afforded the quinone in more than 98% purity (NMR) and in 58% yield (5.65 g).(Ref. 0035) |
Distribution of radioactivity in rats 18 hr after administration of a physiological dose (10 mg) of menadione-6,7-3H to deficient rats showed low levels in liver, heart, kidney, carcass, and viscera while 78-83% of the administered tritium was recovered in the urine during this period. The lipophilic metabolite of menadione, menaquinone-4, was found in all tissues examined.(Ref. 0039) |
|||||||||||||||
26 | Menadione dimethylpyrimidol bisulfate / Hetrazeen. |
1,2-3,4-Tetrahydro-2-methyl--1,4-dioxo-2-naphthalenesulfonic acid compd with 4,6-dimethyl-2(1H)-pyrimidinone(1 : 1) / 2-methyl-1,4-naphthoquinone 2-hydroxy-4,6-dimethylpyrimidine bisufite. |
VVK0026 | Tetsuya Nakamura |
MPB |
C17H18N2O6S | 378.401 | 215 -217(Ref. 0014) |
||||||||||||||||||||
27 | Menadione sodium bisulfite / Golagen K / Hemoklot / Hetrogen K / Hetrogen K Prmix / Hykinone / Ido-K / K-Thrombina / Kalzon / Kavitamin / Kavitan / Kawitan / Klotogen / Klotogen F / Klotogen F 16 / Klotogen F227 / Menadione sodium hydrogen bisulfite / Sodium menadione bisulfite / Vikasol / Vitamin K injection / Vitamin K3 sodium bisulfite. |
1,4-Naphthalenedione, 2-methyl-, sodium bisulfite deriv / 2,3-Dihydro-2-methyl-1,4-naphthoquinone-2-sulfonate sodium / 2-Methyl-1,4-naphthoquinone sodium bisulfonite / 2-Methylnaphthoquinone, sodium hydrogen sulfite. |
VVK0027 | Tetsuya Nakamura |
C11H9NaO5S | 276.242 | The addition of sodium bisulfite to 2-methyl-1,4-naphthoquinone was carried out. The purified colorless crystalline salt obtained from aqueous solution gave analyses indicating approximately four molecules of water of crystallization. The spectrum determined for this material agreed nicely well with the spectrum determined on another specimen which was purified by washing with 95% ethyl alcohol, followed by several recrystallizations from the same solvent; the colorless, nicely crystalline product from 95% alcohol showed the composition of a dihydrate.(Ref. 0040) |
|||||||||||||||||||||
28 | K-lactone |
2- [b-(2-Methyl-5-oxo-tetrahydro-2-furyl)-ethyl]-3-methyl-1,4-naphthoquinone |
VVK0028 | Tetsuya Nakamura |
C18H18O4 | 298.333 | 93 -95(Ref. 0028) |
max245, 253, 271 nm (E1%1cm =573, 555, 569)(Ref. 0029) |
(KBr): 5.66m (g-lactone); 6.04 m (quinone); 6.19, 6.27m (aromatic).(Ref. 0029) |
Singlet at 91 (CH3-4), singlet at 132 (quinone CH3), multiplet at 555-490 (4 aromatic H). (Ref. 0008) |
Five grams of 6-Acetoxy-2-(b-carbomethoxyethyl)-3,4-dihydro-2,5-dimethyl-2H-naphtho-[1,2-b]- pyran(Ref. 0008) is dissolved in 75ml of dioxan, a mixture of 5 ml of water and 5 ml of concentrated sulfuric acid is added, and the solution is reflexed for 3 hours under nitrogen. After cooling, the mixture is diluted with water and worked up as usual to give 4.2 g of red-brown viscous oil. To a solution of this material in 100 ml of methanol are added dropwise with stirring within 10 minutes at room temperature, 110 ml of a solution of 22.5 g of FeCl3. 6H2O in 85 ml of water and 85 ml of methanol. The mixture is stirred longer for 2 hours at room temperatue and the the main part of the methanol is evaporated in vacuo. After saturation with ammonium chloride the mixture is worked up as usual to yield 3.8 g (89%) of a red-brown oil which crystallizes slowly. Recrysatllization from benzene-petroleum ether gives 2.9 g (70%) of the metabolite |
|||||||||||||||||
29 | K acid-I |
2-methyl-3-(5'-carboxy-3'-methyl-2'-pentenyl)-1,4-naphthoquinone |
VVK0029 | Tetsuya Nakamura |
C18H18O4 | 298.333 | Four metabolites of menaquinone-4 (MK-4) were isolated from rat urine, bile and liver. From rat urine following intravenous or oral administration of [14C]MK-4, two major metabolites were isolated and their aglycones were identified as 2-methyl-3-(5'-carboxy-3'-methyl-2'-pentyl)-1,4-naphthoquinone (K acid 1) and 3-(3''-caroxybutyl)-2-methyl-1,4-naphtoquinone (K acid 2). [Table 0003] (Ref. 0003) |
|||||||||||||||||||||
30 | K Acid-II |
2-methyl-3-(3'-carboxybutyl)-1,4-naphthoquinone |
VVK0030 | Tetsuya Nakamura |
C16H15O4 | 271.288 | Four metabolites of menaquinone-4 (MK-4) were isolated from rat urine, bile and liver. From rat urine following intravenous or oral administration of [14C]MK-4, two major metabolites were isolated and their aglycones were identified as 2-methyl-3-(5'-carboxy-3'-methyl-2'-pentyl)-1,4-naphthoquinone (K acid 1) and 3-(3''-caroxybutyl)-2-methyl-1,4-naphtoquinone (K acid 2). [Table 0003] (Ref. 0003) |
|||||||||||||||||||||
31 | No image | 1,4-Naphthalenedione, all trans [3'-14C]2-methyl-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-. |
VVK0031 | Tetsuya Nakamura |
C31H40O2 | 444.648 | Treatment of farnesol (1) with phosphorous tribromide followed by reaction of the bromide product with ethyl [3-14C] acetoacetate (3) gave [3-14C] farnesylacetone (4). Witting reaction of (4) with triethyl phosphonoacetate (5) gave the farnesylcrotonic derivative (6) which was reduced with lithium aluminum hydride to [3-14C] geranylgeraniol (7). Condensation of (7) with menadiol monoacetate (8) followed by hydrolysis and oxidation with silver oxide gave a cis-trans mixture of [3'-14C] menaquinone-4 (11). The mixture was purified by chromatography on silica gel then recrystallization from acetone at -60C to give all trans [3'-14C] menaquinone-4 (tans isomer : more than 96%). The overall radiochemical yield of this synthesis was 12% from (3) [Table 0001]. (Ref. 0033) |
AUTHOR | : | Anonym. (1989) Vitamin K1 in The Merck Index , 11th edition (Budavari, S., O'Neil, M. J., Smith, A., and Heckelman, P.E., eds), pp1580, Merck & Co., Inc., Rahway, N. J. |
TITLE | : | |
JOURNAL | : | |
VOL | : | PAGE : - () |
AUTHOR | : | Dunphy,P.J., and Brodie,A.F. |
TITLE | : | The structure and function of quinones in respiratory metabolism. |
JOURNAL | : | Methods in Enzymology |
VOL | : | 18 PAGE : 407-461 (1971) |
AUTHOR | : | Tadano, K., Yuzuriha, T., Sato, T., Fujita, T., Shimada, K., Hashimoto, K., and Satoh, T. |
TITLE | : | Identification of menaquinone-4 metabolites in the rat PubMed ID:2630633 |
JOURNAL | : | J Pharmacobiodyn. |
VOL | : | 12 PAGE : 640-645 (1989) |
AUTHOR | : | Jackman, L. M., Ruegg, R., Ryser, G., von Planta, C., Gloor, U., Mayer, H., Schudel, P., Kofler, M., and Isler, O. |
TITLE | : | [On the chemistry of vitamin K. 2. Total synthesis and stereochemistry of trans- and cis-(7'R,11'R)-phylloquinone and related compounds] PubMed ID:5846757 |
JOURNAL | : | Helv Chim Acta. |
VOL | : | 48 PAGE : 1332-1349 (1965) |
AUTHOR | : | Di Mari, S. J., Supple, J. H., and Rapoport, H. |
TITLE | : | Mass spectra of naphthoquinones. Vitamin K1(20) PubMed ID:5910960 |
JOURNAL | : | J Am Chem Soc. |
VOL | : | 88 PAGE : 1226-1232 (1966) |
AUTHOR | : | Suttie,W.J. (1991) Vitamin K, in Handbook of Vitamins (2nd ed., Machlin,L.J., ed) , pp145-194, Marcel Dekker, Inc., New York |
TITLE | : | |
JOURNAL | : | |
VOL | : | PAGE : - () |
AUTHOR | : | Kodaka,K., Ujiie,T.,Ueno,T., and Saito,M. |
TITLE | : | Contents of Vitamin K1 and Chlorophyll in Green Vegetables. |
JOURNAL | : | J Jpn Soc Nutr Food Sci |
VOL | : | 39 PAGE : 124-126 (1986) |
AUTHOR | : | Mayer,H., and Isler,O . |
TITLE | : | Synthesis of Vitamin K. |
JOURNAL | : | Methods in Enzymology |
VOL | : | 18 PAGE : 491-547 (1971) |
AUTHOR | : | Naruta,Y., and Maruyama,K. |
TITLE | : | Regio- and sterocontrolled polyprenylation of quinones. A new synthetic method of vitamin K series. |
JOURNAL | : | Chemistry Lett |
VOL | : | PAGE : 881-884 (1979) |
AUTHOR | : | Sommer,P., and Kofler,M. |
TITLE | : | Physicochemical Properties and Methods of Analysis of Phylloquinones, Menaquinones, Ubiquinones, and Related Compounds. PubMed ID:5340867 |
JOURNAL | : | Vitamins and Hormones |
VOL | : | 24 PAGE : 349-399 (1966) |
AUTHOR | : | Bristol, J. A., Ratcliffe, J. V., Roth, D. A., Jacobs, M. A., Furie, B. C., and Furie, B. |
TITLE | : | Biosynthesis of prothrombin: intracellular localization of the vitamin K-dependent carboxylase and the sites of gamma-carboxylation PubMed ID:8839851 |
JOURNAL | : | Blood. |
VOL | : | 88 PAGE : 2585-2593 (1996) |
AUTHOR | : | Anonym. (1989) Menadiol sodium diphosphate in The Merck Index , 11th edition (Budavari, S., O'Neil, M. J., Smith, A., and Heckelman, P.E., eds), pp914, Merck & Co., Inc., Rahway, N. J. |
TITLE | : | |
JOURNAL | : | |
VOL | : | PAGE : - () |
AUTHOR | : | Anonym. (1989) Menadiol dibusulfate in The Merck Index , 11th edition (Budavari, S., O'Neil, M. J., Smith, A., and Heckelman, P.E., eds), pp915, Merck & Co., Inc., Rahway, N. J. |
TITLE | : | |
JOURNAL | : | |
VOL | : | PAGE : - () |
AUTHOR | : | Anonym. (1989) Menadione dimethylpyrimidiol bisulfite in The Merck Index , 11th edition (Budavari, S., O'Neil, M. J., Smith, A., and Heckelman, P.E., eds), pp915, Merck & Co., Inc., Rahway, N. J. |
TITLE | : | |
JOURNAL | : | |
VOL | : | PAGE : - () |
AUTHOR | : | Anonym. (1989) Menadione sodium bisulfite in The Merck Index , 11th edition (Budavari, S., O'Neil, M. J., Smith, A., and Heckelman, P.E., eds), pp915, Merck & Co., Inc., Rahway, N. J. |
TITLE | : | |
JOURNAL | : | |
VOL | : | PAGE : - () |
AUTHOR | : | Baker, B. R., and Carlson, G. H. |
TITLE | : | Water-soluble compounds with antihemorrhagic activity. |
JOURNAL | : | J. Am. Chem. Soc. |
VOL | : | 64 PAGE : 2657-2664 (1942) |
AUTHOR | : | Mayer,H., and Isler,O. |
TITLE | : | Synthesis of vitamin K. |
JOURNAL | : | Methods in Enzymology |
VOL | : | 18 PAGE : 491-547 (1971) |
AUTHOR | : | Hara, K., Akiyama, Y., Nakamura, T., Murota, S., and Morita, I. |
TITLE | : | The inhibitory effect of vitamin K2 (menatetrenone) on bone resorption may be related to its side chain PubMed ID:7756045 |
JOURNAL | : | Bone. |
VOL | : | 16 PAGE : 179-184 (1995) |
AUTHOR | : | Anonym. (1989) Menadiol dibutyrate in The Merck Index , 11th edition (Budavari, S., O'Neil, M. J., Smith, A., and Heckelman, P.E., eds), pp914, Merck & Co., Inc., Rahway, N. J. |
TITLE | : | |
JOURNAL | : | |
VOL | : | PAGE : - () |
AUTHOR | : | Anonym. (1996) Menadione in The Merck Index , 12th edition (Budavari, S., O'Neil, M. J., Smith, A., Heckelman, P.E., and Kinneary, J., F., eds), pp994 Merck & Co., Inc., Whitehouse Station, N. J. |
TITLE | : | |
JOURNAL | : | |
VOL | : | PAGE : - () |
AUTHOR | : | Anonym. (1996) Menadiol in The Merck Index , 12th edition (Budavari, S., O'Neil, M. J., Smith, A., Heckelman, P.E., and Kinneary, J., F., eds), pp994 Merck & Co., Inc., Whitehouse Station, N. J. |
TITLE | : | |
JOURNAL | : | |
VOL | : | PAGE : - () |
AUTHOR | : | Usui, Y., Nishimura, N., Kobayashi, N., Okanoue, T., Kimoto, M., and Ozawa, K. |
TITLE | : | Measurement of vitamin K in human liver by gradient elution high-performance liquid chromatography using platinum-black catalyst reduction and fluorimetric detection PubMed ID:2753953 |
JOURNAL | : | J Chromatogr. |
VOL | : | 489 PAGE : 291-301 (1989) |
AUTHOR | : | Anonym. (1989) Vitamin K5 in The Merck Index , 11th edition (Budavari, S., O'Neil, M. J., Smith, A., and Heckelman, P.E., eds), pp1581, Merck & Co., Inc., Rahway, N. J. |
TITLE | : | |
JOURNAL | : | |
VOL | : | PAGE : - () |
AUTHOR | : | Anonym. (1996) Menaquinone 4, in The Merck Index , 12th edition (Budavari, S., O'Neil, M. J., Smith, A., Heckelman, P.E., and Kinneary, J., F., eds), pp995 Merck & Co., Inc., Whitehouse Station, N. J. |
TITLE | : | |
JOURNAL | : | |
VOL | : | PAGE : - () |
AUTHOR | : | Anonym. (1996) Menaquinone 6, in The Merck Index , 12th edition (Budavari, S., O'Neil, M. J., Smith, A., and Heckelman, P.E., and Kinneary, J., F., eds), pp995 Merck & Co., Inc., Whitehouse Station, N. J. |
TITLE | : | |
JOURNAL | : | |
VOL | : | PAGE : - () |
AUTHOR | : | Anonym. (1989) Vitamin K1 Oxide, in The Merck Index , 11th edition (Budavari, S., O'Neil, M. J., Smith, A., and Heckelman, P.E., eds), pp1580 Merck & Co., Inc., Rahway, N. J. |
TITLE | : | |
JOURNAL | : | |
VOL | : | PAGE : - () |
AUTHOR | : | Anonym. (1989) Vitamin K2(35), in The Merck Index , 11th edition (Budavari, S., O'Neil, M. J., Smith, A., and Heckelman, P.E., eds), pp1580 Merck & Co., Inc., Rahway, N. J. |
TITLE | : | |
JOURNAL | : | |
VOL | : | PAGE : - () |
AUTHOR | : | Anonym. (1989) Vitamin K2(30), in The Merck Index , 11th edition (Budavari, S., O'Neil, M. J., Smith, A., and Heckelman, P.E., eds), pp1580 -1581, Merck & Co., Inc., Rahway, N. J. |
TITLE | : | |
JOURNAL | : | |
VOL | : | PAGE : - () |
AUTHOR | : | Gloor, U., Würsch, J., Mayer, H., Isler, O. and Wiss, O. |
TITLE | : | Stoffwechsel-Endprodukte von Phyllochinon, Menaquinone-4, Ubichuinone-9 und Hexahydroplastochinon-4 (phytylplastochinon). |
JOURNAL | : | Helv. Chim. Acta |
VOL | : | 49 PAGE : 2582-2589 (1966) |
AUTHOR | : | Anonym. (1989) Vitamin K6, in The Merck Index , 11th edition (Budavari, S., O'Neil, M. J., Smith, A., and Heckelman, P.E., eds), pp1581, Merck & Co., Inc., Rahway, N. J. |
TITLE | : | |
JOURNAL | : | |
VOL | : | PAGE : - () |
AUTHOR | : | Anonym. (1989) Vitamin K7, in The Merck Index , 11th edition (Budavari, S., O'Neil, M. J., Smith, A., and Heckelman, P.E., eds), pp1581, Merck & Co., Inc., Rahway, N. J. |
TITLE | : | |
JOURNAL | : | |
VOL | : | PAGE : - () |
AUTHOR | : | Groenen-van Dooren, M. M., Ronden, J. E., Soute, B. A., and Vermeer, C. |
TITLE | : | Bioavailability of phylloquinone and menaquinones after oral and colorectal administration in vitamin K-deficient rats PubMed ID:7575640 |
JOURNAL | : | Biochem Pharmacol. |
VOL | : | 50 PAGE : 797-801 (1995) |
AUTHOR | : | Shimada,K., Tadano, K., Satoh, T., Hashimoto, H., Takada, S., and Yuzuruha, T. |
TITLE | : | Synthesis of all trans [3'-14C] menaquinone-4. |
JOURNAL | : | J. Label. Compds. and Radiopharm. |
VOL | : | 27 PAGE : 1293-1298 (1989) |
AUTHOR | : | Watanabe, M., Toyoda, M., Imada, I., and Morimoto, H. |
TITLE | : | Ubiquinopne and related compounds. XXVI. The urinary metabolites of phylloquinone and a 4-tocopherol. PubMed ID:4833371 |
JOURNAL | : | Chem. Pharm. Bull. |
VOL | : | 22 PAGE : 176-182 (1974) |
AUTHOR | : | Adam, W., Herrmann, W. A., Lin, J., Saha-Möller, C. R., Fischer, R. W., and Correia, J. G. |
TITLE | : | Homgeneous catalytic oxidation of arenes and a new snythesis of vitamin K3. |
JOURNAL | : | Angew. Chem. Int. Ed. Engl. |
VOL | : | 33 PAGE : 2475-2477 (1994) |
AUTHOR | : | Fieser, L. F. and Fry, E. M. |
TITLE | : | Water-soluble antihemorrhagic esters. |
JOURNAL | : | J. Am. Chem. Soc. |
VOL | : | 62 PAGE : 228-229 (1942) |
AUTHOR | : | Thierry, M. J., and Suttie, J. W. |
TITLE | : | Distribution and metabolism of menadiol diphosphate in the rat PubMed ID:5779848 |
JOURNAL | : | J Nutr. |
VOL | : | 97 PAGE : 512-516 (1969) |
AUTHOR | : | Fieser, L. F. |
TITLE | : | Cinvenient procedures for the preparation of antihemorrhagic compounds. |
JOURNAL | : | J. Biol. Chem. |
VOL | : | 133 PAGE : 391-396 (1940) |
AUTHOR | : | Taggart, W. V., and Matschiner, J. T. |
TITLE | : | Metabolism of menadione-6,7-3H in the rat PubMed ID:4181053 |
JOURNAL | : | Biochemistry. |
VOL | : | 8 PAGE : 1141-1146 (1969) |
AUTHOR | : | Carmack, M., Moore, M. B., and Balis, M. E. |
TITLE | : | The structure of the antihemorrhagic sodium bilsulfite addition product of 2-methyl-1,4-naphthoquinone (Menadione). |
JOURNAL | : | J. Am. Chem. Soc. |
VOL | : | 72 PAGE : 844-847 (1950) |
AUTHOR | : | Verdstra, H., and Wiardi, P. W. |
TITLE | : | Water soluble antihemorrhagic substances I. Synthesis of 2-methyl-1,4-aminonaphthol-1 hydrochloride and 2-methyl-1,4-diaminonaphthalene dihydrochloride, the water soluble synthetic vitamins K5 and K6. |
JOURNAL | : | Rec. Trav. Chim. |
VOL | : | 62 PAGE : 75-84 (1943) |